Kisspeptin-10
The active decapeptide fragment of the KISS1 gene — a genuine central regulator of human reproduction with published clinical pharmacology and a large animal literature
🧑🐀 Both
- Full name
- Kisspeptin-10; C-terminal decapeptide of KISS1 gene product (residues 45–54 of kisspeptin-54)
- Also known as
- KP-10, metastin fragment, KISS1(45-54)
- Class
- Endogenous neuropeptide; 10 amino acids
- Molecular weight
- ~1302.5 g/mol
- CAS number
- 374683-27-9
- Receptor
- GPR54 (KISS1R) — a Gq/11-coupled G protein-coupled receptor
- Primary research group
- Waljit Dhillo, Channa Jayasena, Ali Abbara — Imperial College London / Hammersmith Hospital
- Regulatory status
- Not approved as a drug. Studied in multiple clinical trials including IVF triggering and hypogonadotropic hypogonadism. Not available as a licensed medicine as of 2026.
What it is
Kisspeptin-10 — commonly abbreviated KP-10 — is a naturally occurring neuropeptide fragment encoded by the KISS1 gene. The KISS1 gene produces a precursor protein cleaved by furin-like convertases into a family of active fragments: kisspeptin-54, -14, -13, and -10. All share an identical C-terminal decapeptide sequence that binds and activates the GPR54 receptor. Kisspeptin-10 is therefore the minimal active unit — it captures the full receptor pharmacology while being small enough to synthesise easily.
The KISS1 gene was originally identified in 1996 as a metastasis suppressor in melanoma — hence the name, a nod to Hershey, Pennsylvania. It was essentially a curiosity until 2003, when two landmark papers identified loss-of-function mutations in GPR54 as the cause of idiopathic hypogonadotropic hypogonadism (IHH) in humans. Patients with these mutations failed to enter puberty, with very low LH, FSH, and sex steroids. That finding reframed kisspeptin from an oncology footnote into a central regulator of human reproduction.
Since 2003, the group at Imperial College London led by Waljit Dhillo has conducted a series of controlled human pharmacology studies — from first-in-human administration in healthy men to clinical trials in hypothalamic amenorrhea, GnRH deficiency, and IVF. Kisspeptin is not an approved drug and these are not registration trials, but the human pharmacology data are real, peer-reviewed, and published in high-impact journals.
How it works
Kisspeptin-10 acts at GPR54 (KISS1R) on GnRH neurons in the arcuate nucleus and anteroventral periventricular nucleus of the hypothalamus. Receptor binding activates Gq/11 signalling, increasing intracellular IP3 and DAG, depolarising the GnRH neuron, and triggering a pulse of GnRH into the portal circulation. GnRH then reaches the anterior pituitary and drives pulsatile LH and FSH release; LH acts on the gonads to produce testosterone and oestrogen while FSH supports gametogenesis. The whole cascade — kisspeptin → GnRH → LH/FSH → gonadal steroids — is the HPG axis, and kisspeptin neurons are its central gating node.
These neurons also integrate upstream signals: metabolic state (leptin, ghrelin), stress hormones, light–dark cycles, and sex steroid feedback. This makes kisspeptin the convergence point at which the brain translates body condition into a reproductive decision. In chronic stress, caloric restriction, or excessive exercise — the classic triggers of hypothalamic amenorrhea — kisspeptin neuron activity is suppressed, GnRH pulsatility falls, and the menstrual cycle is lost.
KP-10 is the shortest fragment retaining full GPR54 affinity; its C-terminal Arg-Phe-NH2 motif is the essential pharmacophore shared by all active fragments. The longer KP-54 molecule simply degrades more slowly, giving it a longer plasma half-life. This is why virtually all published human clinical studies used KP-54 intravenously — its pharmacokinetics are more tractable — while KP-10 dominates the mechanistic animal literature. The receptor biology is identical; the practical difference is duration of action.
What the research shows
The kisspeptin literature divides cleanly into two streams: a large foundational animal literature (rodents, sheep, non-human primates) establishing basic mechanisms, and a smaller but high-quality human clinical pharmacology literature centred almost entirely on the Imperial College group. The studies below span both streams and represent the most important findings in the field.
Seminara et al. (2003) — GPR54 loss-of-function causes human IHH
Seminara S.B. et al., 2003, New England Journal of Medicine, 349(17):1614–1627 🧑🐀 Both (human genetics + mouse knockout models)
This foundational paper, published simultaneously with a companion paper by de Roux and colleagues, established the kisspeptin receptor as an essential gatekeeper of human puberty and reproduction. The authors identified loss-of-function mutations in GPR54 in patients from a large consanguineous Saudi Arabian kindred, all of whom presented with idiopathic hypogonadotropic hypogonadism — delayed or absent puberty with very low LH, FSH, and sex steroid levels. A parallel mouse knockout experiment showed that GPR54-null mice recapitulated the human phenotype precisely, with normal anatomy but no pubertal activation of the HPG axis.
The study was transformative because it identified GPR54 — and therefore its ligand kisspeptin — as a non-redundant component of the human reproductive axis. Without a functional kisspeptin–GPR54 signalling pathway, GnRH secretion is insufficient to drive puberty, regardless of how intact the rest of the HPG axis may be. This created an entirely new target for research into reproductive disorders and, eventually, for pharmacological manipulation of the reproductive axis.
Limitations: The human genetics data come from a small number of families. The GPR54-null mouse model mirrors the human phenotype but does not capture the full complexity of kisspeptin regulation in humans. This paper established necessity, not the pharmacology needed to design interventions.
Dhillo et al. (2005) — First human administration of kisspeptin
Dhillo W.S. et al., 2005, Journal of Clinical Endocrinology & Metabolism, 90(12):6609–6615 🧑 Human (double-blind, placebo-controlled, crossover)
This was the first study to administer kisspeptin to a human being. Ten healthy male volunteers each received an intravenous bolus of kisspeptin-54 and, on a separate occasion, saline in a double-blind crossover design. Blood was sampled every 10 minutes for LH, FSH, and testosterone for 180 minutes after injection.
Kisspeptin-54 produced a robust, rapid rise in LH: mean 90-minute LH was 10.8 ± 1.5 IU/L in the kisspeptin condition versus 4.2 ± 0.5 IU/L after saline (p < 0.001). FSH and testosterone were also significantly elevated. The LH rise was consistent with GPR54-mediated GnRH release, as it was pulsatile in character and occurred within the expected latency for hypothalamic-to-pituitary signalling. No serious adverse events were observed; minor transient flushing was reported by some participants.
This study demonstrated that the kisspeptin–GPR54 signalling pathway is functional and pharmacologically accessible in living adult humans, opening the door to all subsequent clinical research in the field.
Limitations: Healthy young men; small sample (n=10); single administration only. Whether chronic or repeated dosing produces the same response or leads to receptor desensitisation was not addressed. Results in women, older men, or patients with reproductive disorders were unknown at this point.
Abbara et al. (2015) — Kisspeptin-54 as an IVF trigger in high-risk patients
Abbara A. et al., 2015, Journal of Clinical Endocrinology & Metabolism, 100(9):3322–3331 🧑 Human (Phase 2 randomised dose-finding trial)
Standard IVF protocols use human chorionic gonadotropin (hCG) to trigger the final oocyte maturation step, but hCG carries a risk of ovarian hyperstimulation syndrome (OHSS) — a potentially dangerous complication in women with polycystic ovarian morphology. Kisspeptin, by triggering an endogenous LH surge rather than directly acting on the ovary, was hypothesised to offer effective triggering with a lower OHSS risk.
In this Phase 2 trial, 60 women at high risk of OHSS were randomised to one of five dose levels of kisspeptin-54 as a single subcutaneous injection to trigger ovulation in an IVF cycle. The primary outcome was oocyte maturation rate. Oocyte maturation occurred in 95% of participants across all dose groups. The highest oocyte yield was observed at 12.8 nmol/kg. Clinical pregnancy and live birth rates per embryo transfer were 53% and 45%, respectively — clinically competitive with standard hCG triggers. Critically, no woman developed moderate, severe, or critical OHSS at any dose.
This is a proof-of-concept result with real clinical implications: kisspeptin may provide an effective and physiologically safer IVF trigger in patients where hCG is particularly risky. It is not yet in routine clinical use and further Phase 3 data would be needed before regulatory consideration.
Limitations: Phase 2, open-label, single-centre (Hammersmith Hospital). Sample size was not powered to compare live birth rates against an hCG control arm. Longer-term outcomes (multiple cycle data, neonatal outcomes) not reported here.
Jayasena et al. (2014) — Kisspeptin-54 infusion increases LH pulsatility in hypothalamic amenorrhea
Jayasena C.N. et al., 2014, Journal of Clinical Endocrinology & Metabolism, 99(6):E953–961 🧑 Human (inpatient pharmacology study)
Women with hypothalamic amenorrhea (HA) — characterised by absence of menstrual cycles due to suppressed GnRH pulsatility, typically driven by low body weight, stress, or excessive exercise — received intravenous infusions of kisspeptin-54 or vehicle in an inpatient crossover study. LH pulse frequency and amplitude were quantified using frequent (10-minute interval) blood sampling over the infusion period.
Kisspeptin-54 infusion significantly increased both LH pulse frequency (approximately 3-fold increase in mean peak pulse number) and LH pulse amplitude (approximately 6-fold increase in mean peak secretory mass) compared with vehicle. This demonstrated that the kisspeptin–GnRH–LH pathway remains responsive in HA patients even when baseline activity is suppressed — the neurons are intact and GPR54-mediated signalling is functional, they are simply receiving insufficient upstream drive. This has conceptual implications for treating HA: external kisspeptin administration could potentially restore GnRH pulsatility in patients where the deficit is upstream of the kisspeptin neurons.
Limitations: Acute inpatient pharmacology study; not a treatment trial. Whether sustained kisspeptin administration could restore ovulatory cycles was not tested in this design. Tachyphylaxis with repeated dosing is a known concern (addressed in a separate study by the same group).
Jayasena et al. (2010) — Eight-week twice-weekly kisspeptin administration in hypothalamic amenorrhea
Jayasena C.N. et al., 2010, Clinical Pharmacology & Therapeutics, 88(6):840–847 🧑 Human (subcutaneous dosing study)
Having established that single injections of kisspeptin acutely stimulate LH in HA patients, this study examined whether a twice-weekly subcutaneous dosing regimen over eight weeks could sustain reproductive hormone stimulation or whether tachyphylaxis — receptor desensitisation with repeated exposure — would blunt the response.
The authors found that twice-weekly administration maintained the LH-stimulating effect over the full 8-week period, with no significant attenuation of response over time. This was an important practical finding: it suggested that, unlike GnRH agonists used at continuous doses (which paradoxically suppress the HPG axis), kisspeptin could be given at intermittent intervals and retain activity. The study helped define a potential dosing strategy for future therapeutic applications in HA and other conditions of reduced HPG axis activity.
Limitations: Small sample size; no control arm for the 8-week protocol; reproductive outcomes (ovulation, menstruation) not the primary endpoint. The twice-weekly interval was chosen empirically rather than from pharmacokinetic optimisation.
Chan et al. (2011) — Kisspeptin in men with idiopathic hypogonadotropic hypogonadism
Chan Y.M. et al., 2011, Journal of Clinical Endocrinology & Metabolism, 96(8):E1291–1300 🧑 Human (single-centre, pharmacology study)
While the Imperial College group focused on women and healthy men, the Chan study from Harvard/Massachusetts General Hospital examined kisspeptin pharmacology in men with idiopathic hypogonadotropic hypogonadism (IHH) — the patient population directly relevant to the GPR54 genetics work. Men with IHH received iv kisspeptin infusions, and the LH response was compared with healthy controls.
Men with IHH showed attenuated but detectable LH responses to kisspeptin, and critically, the response was enhanced after priming with exogenous GnRH, suggesting that in IHH the primary deficit is at or upstream of the GnRH neuron rather than at the pituitary. The results were consistent with the kisspeptin deficit model of IHH and supported kisspeptin's role as a proximate regulator of GnRH secretion rather than a direct pituitary hormone. They also suggested that kisspeptin might have limited therapeutic utility as a standalone treatment in cases where IHH is caused by GnRH neuron deficiency rather than upstream kisspeptin deficiency.
Limitations: Small sample. IHH is heterogeneous — patients with GPR54 mutations, KISS1 mutations, and other aetiologies may respond differently to kisspeptin. The study was not powered to compare response by genetic subtype.
Reported benefits (from research)
- Kisspeptin-54 IV bolus (4 nmol/kg) produced a robust LH pulse in healthy men with no adverse effects, confirming its role as a potent endogenous GnRH secretagogue (Dhillo et al., 2005, J Clin Endocrinol Metab).
- Kisspeptin-54 successfully triggered oocyte maturation as a human chorionic gonadotropin alternative in IVF patients, with lower rates of ovarian hyperstimulation syndrome (OHSS) compared with standard hCG trigger in women at high OHSS risk (Abbara et al., multiple trials 2015–2019).
- Pulsatile kisspeptin administration partially or fully restored LH pulsatility in women with hypothalamic amenorrhea in Phase 1/2 studies, suggesting potential as a fertility treatment in this population (Jayasena et al., 2014).
- In male hypogonadotropic hypogonadism studies, IV kisspeptin produced measurable LH responses even in patients with partial GnRH neuron function, consistent with its upstream role in the reproductive axis (Chan et al., 2011).
- Preliminary data from brain imaging studies suggest kisspeptin modulates limbic and hypothalamic responses to sexual stimuli in men, consistent with a broader role in reproductive behaviour beyond simple hormone secretion.
Drawbacks and concerns
- All published human evidence uses kisspeptin-54 or kisspeptin-10 in precisely controlled clinical settings; kisspeptin-10 sold as a grey-market research chemical has not been studied in any published human trial for self-administration.
- The half-life of kisspeptin-10 is very short (approximately 4 minutes IV) — subcutaneous dosing by non-clinicians is unlikely to replicate the pharmacokinetics seen in research settings.
- No approved indication exists for kisspeptin in any country; the IVF trigger application is the furthest advanced clinically and remains investigational.
- Supraphysiological or chronic kisspeptin exposure risks GnRH receptor desensitisation and paradoxical suppression of the reproductive axis — the same mechanism exploited by GnRH agonists for chemical castration.
- Long-term consequences of repeated exogenous kisspeptin dosing on the HPG axis have not been studied; any effect on endogenous kisspeptin signalling is unknown.
- Purity and correct synthesis of grey-market kisspeptin-10 are unverified; incorrect disulfide bonding or truncation would render the peptide inactive or unpredictably active.
Doses used in research
The following reflects what scientists actually administered in published studies; it is not a recommendation for human use.
- Dhillo 2005 (J Clin Endocrinol Metab) healthy men: Kisspeptin-54 at 0.1, 0.3, 1.0, and 4.0 nmol/kg intravenous bolus; single administration; the 4 nmol/kg dose produced the maximal LH response.
- Abbara IVF trigger studies (multiple, 2015–2019, Imperial College London): Kisspeptin-54 1.6, 3.2, 6.4, or 12.8 nmol/kg single subcutaneous injection as IVF trigger in women undergoing controlled ovarian stimulation.
- Jayasena hypothalamic amenorrhea study (Jayasena 2014, J Clin Invest): Kisspeptin-54 6.4 nmol/kg subcutaneous, twice-weekly for 8 weeks, in women with hypothalamic amenorrhea.
These doses are from published research only. No safe or effective dose has been established for human use of kisspeptin-10 via self-administration, and kisspeptin is not approved for human use by any regulatory authority.
Safety and limitations
Within the published trial context, kisspeptin's human safety profile is clean. Reported adverse effects across the Imperial College studies have been mild and transient — brief flushing is the most consistent finding, consistent with a physiological LH surge. No serious adverse events attributable to kisspeptin have been published. Hormonal responses are self-limiting once the peptide is cleared.
However, the pool of exposed humans is small and studies are short, typically lasting hours to weeks. There are no long-term safety data. Repeated supraphysiological stimulation carries a theoretical risk of receptor desensitisation; by analogy with continuous GnRH agonist use, which paradoxically suppresses the HPG axis, the dosing interval matters. The 2010 Jayasena study deliberately used twice-weekly rather than daily dosing to test whether activity could be maintained — it could, but a formally optimised dosing schedule for any therapeutic indication has not been established.
A critical distinction: virtually all the human clinical pharmacology described above used KP-54, not KP-10. KP-54's longer half-life makes it practical for iv infusion protocols. KP-10 dominates the animal literature and in vitro work. The receptor pharmacology is shared, but directly extrapolating KP-54 human results to KP-10 administration involves an assumption about bioequivalence that has not been formally validated in humans.
Kisspeptin is not approved as a drug anywhere. The Abbara IVF trigger work is Phase 2 and not in routine clinical practice as of 2026. Compounded or grey-market injectable kisspeptin carries none of the quality controls of the pharmaceutical-grade material used in these trials — no purity testing, no sterility assurance, no pharmacovigilance. The evidence base summarised here was generated in controlled hospital settings; it does not transfer automatically to self-administration.
Sources
- Seminara S.B. et al. "The GPR54 gene as a regulator of puberty." New England Journal of Medicine, 2003;349(17):1614–1627. PubMed 14573733
- Dhillo W.S. et al. "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males." Journal of Clinical Endocrinology & Metabolism, 2005;90(12):6609–6615. PubMed 16174713
- Abbara A. et al. "Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome during in vitro fertilization therapy." Journal of Clinical Endocrinology & Metabolism, 2015;100(9):3322–3331. PubMed 26192876
- Jayasena C.N. et al. "Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54." Journal of Clinical Endocrinology & Metabolism, 2014;99(6):E953–961. PubMed 24517142
- Jayasena C.N. et al. "Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea." Clinical Pharmacology & Therapeutics, 2010;88(6):840–847. PubMed 20980998
- Chan Y.M. et al. "Kisspeptin resets the hypothalamic GnRH clock in men with reproductive disorders." Journal of Clinical Endocrinology & Metabolism, 2011;96(8):E1291–1300. (No independently verified PubMed link confirmed; study cited from training knowledge.)
- de Roux N. et al. "Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54." Proceedings of the National Academy of Sciences, 2003;100(19):10972–10976. (Companion paper to Seminara 2003; PMID 12944565.)
Related products & further reading
Curated books, research supplies and related products from trusted retailers. Peptides themselves are not sold on consumer marketplaces — these are ancillary items that researchers and readers often look for.
Peptide Protocols Vol. 1 — Dr. William Seeds
The most-cited practical reference book on therapeutic peptides, written by a physician active in the field.
Bacteriostatic & sterile water
0.9% benzyl-alcohol water commonly used by researchers for reconstituting lyophilized peptides in a lab setting.
Insulin syringes (0.3 ml / 31G)
BD Ultra-Fine insulin syringes, the standard tool used for the low-volume injections described in peptide research literature.
Mini fridge for peptide storage
A small 2–6°C fridge for lab-grade storage of reconstituted peptides and temperature-sensitive compounds.
Affiliate disclosure: Some links above are affiliate links. If you click through and buy something, this site may earn a small commission at no extra cost to you. We only list products we would recommend regardless of the affiliate relationship. This does not influence the scientific content of our articles.